Martin H. Voss, MD, an assistant attending at Memorial Sloan Kettering Cancer Center, discusses recent data supporting the use of neoadjuvant therapy in patients with locally advanced kidney cancer.
One of the biggest concerns with neoadjuvant approaches compared with adjuvant treatments for nonmetastatic disease is whether neoadjuvant therapies will delay the timing of surgeries, according to Voss. Most of the drugs used in the neoadjuvant setting have proven to work well with subsequent surgery and have not postponed timing.
Concerns regarding the effect of toxicities on surgery have also come up, but Voss says new data suggest otherwise. Voss said that the data also suggest that use of neoadjuvant therapies in kidney cancer does not negatively affect a patient’s survival or cause any operative complications.
For more resources and information regarding anticancer targeted therapies and the latest advancements in Kidney Cancer: [ Ссылка ]
